Michael Seed graduated in Pharmacology, with a PhD, from the University of Bath, followed by a short term lectureship. Having had a placement in experimental surgery and toxicology with Huntingdon Life Sciences, he joined the pharmaceutical industry (with Roussel Laboratories and then Hoechst) in arthritis Drug Discovery centring on in arthritis and angiogenesis disease modelling, drug screening and target validation, centring on leflunomide analogues, phospholipase A2 and matrix metalloproteinase inhibitors. He continued his development of inflammatory and cancer disease models, concentrating on transdermal drug delivery, joint destruction, and angiogenesis in the Department of Experimental Pathology, Saint Bartholomew’s Medical College, as an Honorary Senior Lecturer, and then Joint Head of the Experimental Pathology Group at Barts & the London School of Medicine & Dentistry.  He held a William Harvey Inflammation Research Fellowship for some years and a Sir Halley Stewart Trust Lectureship lecturing and researching in inflammopharmacology and drug discovery in the Centre for Experimental Medicine and Rheumatology. He lectured and examined on the MBBS and intercalated BMedSci programmes, as well as the MBBS Graduate Entry Programme, and still has role in these as an Honorary Senior Lecturer.

Pharmacology Teaching

Inflammopharmacology Research

Biotech / Drug Discovery Consulting

School Postgraduate Research Degrees Committee

School Research Ethics committee

Areas of interest/Summary of Expertise:

Drug discovery in inflammation and rheumatology.

Integrative modelling of inflammatory and rheumatic disease

Drug target identification and translational modelling

The 3Rs in inflammation research.

• BSc (Hons) Pharmacology
• MSc Cellular and Molecular Pharmacology
• MRes Pharmacology

Module Leader

• BS3041 - Systems Pharmacology
• BS3042 - Behavioural and Chemical Pharmacology
• BSM019 - Systems Pharmacology
• BSM020 - Behavioural and Chemical Pharmacology

Teach on:

• BS3016 - Cellular Pathology, Haematology and Transfusion Science
• BS3035 - Clinical Physiology & Employability
• BS3034 - Applied Toxicology
• BS3063/4/5 - Individual Research Project & Employability
• BS2041 - Introductory Pharmacology
• BS2042 - Neuropharmacology
• BS2050 - Physiological regulation
• BSM2041 - Introductory Pharmacology
• BSM2042 - Neuropharmacology
• BSM002 - Research Skills
• BSM012 - Applied Toxicology
• BS1010 - Human Health and Disease

Current research

Auto-immune diseases, including rheumatoid arthritis, are crippling, very painful and lead to an early death. Dr Seed’s research focuses on the discovery and proof of concept of molecular targets amenable to orally active low molecular weight new chemical entities. These are the next generation of anti-autoimmune therapeutics aimed to replace current biologic treatments. Research centres on in vitro and in vivo modelling and molecular analysis of immune and auto-immune disease mechanisms and the associated tissue destruction.

PI3kinase has been a major interest, funded through the William Harvey Research Foundation. As part of the MACROCEPT EU CRAFT and KINACEPT EUFP7 programmes, the long term cellular effects of p38MAP-kinase inhibitor responses is being investigated with the aim of improving their potential in the clinic.

A collaboration with the University of Manchester on the Wellcome Trust Seeding Drug Discovery Initiative ‘Selective glucocorticoid receptor agonists for the treatment of inflammatory conditions’ is designing novel anti-rheumatic steroids whose anti-inflammatory properties are dissociated from the life-threatening side effects associated with this drug class. This research adds in silico drug design, chemical synthesis, and gene trans-activation and trans- repression screening in the collaboration, to this laboratory which will differentiate the in vivo anti-rheumatic activity of dissociated steroids from their osteopenic and diabetic side effects. In collaboration with Prof Alan Boyde, Barts Dental Institute, this has involved research and characterisation of new methods of determining steroid induced bone remodelling in rodents utilising XRay, μCT, fluorescent confocal immunohistology, and scanning electron microscopy in collaboration.

The mechanistic studies of a newly invented set of orally active anti-rheumatic and anti-erosive heparinoid-like NCEs that modulate inflammatory cell adhesion responses and cytokine synthesis profiles, as well as HSV/HIV immune cell interactions are being pursued. The Gordon van Armand Prize research into the role of IKKα in type IV hypersensitivity responses.  dendritic cell – T cell interactions which has been published recently.

Journal Publications

1. I-kappa B kinase (IKKα) activity is required for functional maturation of dendritic cells and acquired immunity to infection. Mancino A, Habbedine M, Johnson E, Luron L, Bebien M, Bajenoff M, Wu X, Karin M, Caamano, Seed MP, Lawrence T. EMBO J 2013 epub Feb 19.
2. Mapping pathogenesis of arthritis through small animal models. Vincent TL, Williams RO, Maciewicz R, Silman A, Garside P; for the Arthritis Research UK animal models working group. Rheumatology 2012 51: 1931-41.
3. The impact of the Annexin A1 pathway on glucocorticoid control of inflammatory arthritis. HB Patel, K Kornerup, ALF Sampaio, AP Girol, F D’Acquisto, MP Seed, M Gray, C Pitzalis, SM Oliani and M Perretti. Arthritis Rheumatism 2012 Ann Rheum Dis 71:1872-80.
4. Molecular engineering of short half-life small peptides (VIP, α-M|SH and Υ3MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, Chernajovsky Y. Ann Rheum Dis 2012 71:143-9.
5. The Melanocortin Agonist AP214 Exerts Anti-Inflammatory and Pro-resolving Properties. Montero-Melendez T, Patel HB, Seed M, Nielsen S, Jonassen TE, Perretti M. Am J Pathol 2011 179(1):259-269.
6. Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404. Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D. Drug Metab Dispos 2011 39: 1689-95.
7. Inhibition of the diclofenac-induced cyclooxygenase-2 activity by paracetamol in cultured macrophages is not related to the intracellular lipid hydroperoxide tone. Ayoub S, Joshi A, Chol M, Seed MP.  Fundamental & Clinical Pharmacology 2011, 25:186-190.
8. Human single chain fragment variable (scFv) that specifically targets arthritic cartilage. Hughes C, Faurholm B, Dell'accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, De Bari C, Winyard P, Chernajovsky Y, Nissim A. Arthritis Rheum. 2010 62(4): 1007-1016.
9. Development of disease-modifying treatments for rheumatoid arthritis. Seed MP. Pharm J. 2009. 282:191-192.
10. Activation of macrophage peroxisome proliferator-activated receptor- by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Ayoub SS, Botting RM, Joshi A, Seed MP, Colville-Nash PR. Mol. Cell. Biol. 2009 327:101–110.  

Patents

Formulations of active pharmaceutical ingredients using normal human metabolites. SEED M, Burnet MW, Galvez J. Application number: 61502802. Status: Submitted. Filed date: 29 Jun 2011.

Combinations comprising an anti-inflammatory agent and/or an antibacterial agent and a glycosylamine and their use in medicine. JM Galvez, MP Seed, IM Roitt, M Burnet - WO patent WO/2011/083,291, 2011.

Novel Compounds. SEED M, Burnet M, Gutche HJ. Patent Number: WO Patent 2,008,059,003, 2008.

Modification of cytokine levels with glucosylamine compounds. MP Seed, JA Mancini, L Dugo, M Lees, M Burnet… - WO patent WO/2008/152,421, 2008.

Treatment of inflammation or autoimmune diseases with sulphated compounds. MP Seed, JA Mancini, L Dugo, M Lees, M Burnet… - WO patent WO/2008/152,423, 2008.

New Methods. SEED M, Mancini M, Lees M, Dugo L. Status: Unpublished. Filed date: 31 Oct 2008.

Use of Sulphated saccharides in the treatment of inflammatory and/or other Inflammatory Diseases. Mancini J, Dugo L, Seed M, Lees M, Burnet M, Gutke HJ. Application number: 0711139.5. Status: Published. Filed date: 11 Jun 2007.

Pharmaceutical compositions comprising an angiostatic steroid combined with a hyaluronan title: compositions pharmaceutiques comprenant un steroide angiostatique combine a un hyaluronan. SEED M, Alam C, Willoughby DA. Patent number: WO Patent WO1999001142, 1999.

Promotion of wound healing utilizing steroids having reduced deleteriorous  systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids. / Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels. Alam Chandan, Seed Michael P, Willoughby Derek A:.  Patent Number: CA 2208916, 1999.

Books

Angiogenesis in Inflammation. Walsh D, Seed M. Progress in Inflammation Research. Birkhauser, Basel. 2008.

Cyclo-oxygenases:  Methods and Protocols. Ayoub S, Flower RJ, Seed M 2010. Humana Press 2010.

Book Chapters

Synovial Pathobiology of Rheumatoid Arthritis. Pitzalis C, Humby F, Seed MP. In: Oxford Textbook of Rheumatology 2012.

Animal Models of Rheumatoid Arthritis. Patel HB, Dawson B, Humby F, Blades M, Pitzalis C, Burnet M, Seed M. Fundamentals of Inflammation. Eds Gilroy D & Serhan C. 2010. Cambridge University Press. pp: 384-441.

Cyclo-oxygenase enzymes and their products in the carrageenan-induced pleurisy in rats. Moore AR, Ayoub SS, Seed MP. Methods Mol Biol. 2010; 644:201-5.

 Book Chapters

1. The assessment of inflammation, cartilage matrix and bone loss in experimental mono-articular arthritis in the rat. Seed MP, (2003) Methods Mol Biol 225: 161-174.
2. Angiogenesis. Winkler JD, Jackson JR, Fan T-P, Seed MP (1999). In: In vivo models of Inflammation (eds Morgan DW & Marshall LA). Progress in Inflammation Research 93-109.
3. Inflammatory angiogenic factors in a model of chronic inflammation. Winkler J, Seed MP, Jackson JR (1998). In: NATO ASI Series Angiogenesis: Models, Modulators, and Clinical Applications.
4. The role of the inducible enzymes cycloxygenase-2, nitric oxide synthase, and heme oxygenase in inflammation angiogenesis. Seed M, Gilroy D, Paul-Clark M, Tomlinson A, Willoughby DA (1999). In: Inducible Enzymes in the Inflammatory Response (eds Willoughby DA, Tomlinson A. Progress in Inflammation Research 125-148.
5. Modelling angiogenesis in inflammation. Alam CAS, Colville-Nash PR, Seed MP. Progress in Inflammation Research 2008: 99-148.
6. Endogenous mediators of pain and inflammation. Ehrenstein M, Isenberg D, Seed MP. (1996). Pharmacology in the practice of Anæsthesia. Eds Kaufman L & Taberner P. Arnold Ltd UK. pp 385-416.
7. Hypothesis: a link between analgesia and angiostasis induced by hyaluronan and diclofenac during inflammation in vivo. Alam CAS, Seed MP, Willoughby DA (1996). In: Management of Pain, a World Perspective. Eds Prithvi RAJ, Erdine S, Niv D, Raja S. Monduzzi Editore.Bologna. pp 629-633.

Journal Articles

1. Editorial: Ethics. Seed MP, Rainsford KD. Inflammopharmacology 15 (2007) 181–182.
2. Randomized double blind multicentre clinical trial to assess the efficacy of glucosamine/chondroitin sulphate for the treatment of dogs with osteoarthritis.  McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. Veterinary Journal, (2007), 174(1):54-61.
3. Study of a combined percutaneous local anaesthetic and the TDS® system for venepuncture. Tucker AT, Chik Z, Michaels L, Seed MP, Johnston A, and Alam CAS (2006) Anaesthesia, 2006, 61, pages 123–126.
4. The inhibition of neutrophil–endothelial cell adhesion by hyaluronan independent of CD44. M. P. Seed, C. Freemantle, J. Brown, M. Perretti, M. Carrier, A. Divwedi, D. C. West, S. Gustafson, C. A. S. Alam, P. R. Colville-Nash, D. A. Willoughby (2005). Inflammopharmacology 12(5-6) 535-550.
5. The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Myobacterium tuberculosis. M. P. Seed, C. R. Gardner (2005). Inflammopharmacology 12(5-6) 551-567.
6. Heat shock proteins and their role in chondrocyte protection, an application for autologous transplantation. D. A. Sawatzky, R. Foster, M. P. Seed, D. A. Willoughby (2005). Inflammopharmacology 12(5-6), 569-589.
7. Reading at the service of thanksgiving for the life and work of Professor Derek Albert Willoughby, PhD, DSc, FIBiol, FRCPath, FMedSci. Michael Seed. (2005). Inflammopharmacology 12(5-6) 449-451.
8. Comment on: Prostaglandin F2α produced by inducible cyclooxygenase may contribute to the resolution of inflammation (2005). C. Alam, M.P. Seed. Inflammopharmacology 12(5-6) 477-480.
9. Relationship between apoptosis, angiogenesis and colon-26 tumour growth after oral NSAID-treatment. Brown JR, Seed MP, Willoughby DA (2003) Adv Exp Med Biol. 507:409-14.
10. Sulphated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis. McCarty MF, Russell AL, Seed MP (2000). Medical Hypotheses 54:798-802.
11. The effects of cyclooxygenase-2 inhibitors on cartilage erosion and bone loss in a model of mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Gilroy D, Tomlinson A, Greenslade K, Seed MP, Willoughby DA (1998).  Inflammation 22:509-519.
12. Mechanisms of the anti-inflammatory activity of low-dose ionizing radiation. Hildebrandt G, Colville-Nash PR, Freemantle CN, Trott KR, Seed MP. (1998) Int. J Radiat. Biol. 74: 367-378.
13. Effects of low dose ionizing radiation on murine chronic granulomatous tissue. Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR (1998). Strahlenther Onkol. 174(11):580-8.
14. Tetrahydro-derivatives of cortisone promote granulomatous tissue angiogenesis in vivo on topical application in hyaluronan. Alam CAS, Colville-Nash PR, Seed MP, Willoughby DA  (1997) Angiogenesis 1:185-191.
15. Angiogenesis in inflammatory disease. Winkler JD, Seed MP (1997). Inflammation Research 46: 157-158.
16. Cox-2, HO NO! Cyclooxygenase-2, heme oxygenase and nitric oxide synthase: Their role and interactions in inflammation. Meeting report. Seed MP, Willoughby DA (1997) Inflammation Research 46: 279-281.
17. The codependence of angiogenesis and inflammation. Jackson J, Winkler J, Seed MP, Willoughby DA (1997). FASEB J 11:457-465.
18. Apoptosis induction and inhibition of colon-26 tumour growth and angiogenesis: Findings on COX-1 and COX-2 inhibitors in vitro & in vivo and topical diclofenac in hyaluronan. Seed MP, Freemantle CN, Alam CAS, Colville-Nash PR, Brown JR, Papworth JL, Somerville KW, Willoughby DA (1997). Adv Exp Med Biol. 1997;433:339-42.
19. The inhibition of Colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Seed MP, Brown JR, Freemantle CN, Papworth JL, Colville-Nash PR, Willis D, Somerville KW, Asculai S, Willoughby DA (1997). Cancer Research 57: 1625-1629.
20. Topical drug vehicle effects on skin and inflammation. Seed MP, Papworth JL, Alam CAS, Willoughby DA (1997). Inflammation Research 46:191-192.
21. Angiogenesis as a target for therapy - An update. Seed MP.(1996) Expert Opin Invest Drugs 5:1617-1637.
22. Proteoglycan degrading activity in granulomatous inflammation: comparison between the C57bl/6 and C57bg/bg mouse. Prigent D, Trancart MM, Seed MP, Willoughby DA (1996). Inflammation Research 45:494-498.
23. Anti-tumour activity of the dual cyclo-oxygenase -1/2 inhibitor diclofenac in combination with hyaluronan. Seed MP, Freemantle CN, Papworth J, Brown JR, Willoughby DA (1996) Royal Society of Medicine Round Table Series 45:59-67.
24. Resident granulomatous tissue and tumour prostaglandin synthesis inhibition by topical diclofenac in hyaluronan. Papworth J, Seed MP, Willoughby DA (1996) Royal Society of Medicine Round Table Series 45:54-58.
25. The depletion of substance-P by diclofenac formulated in hyaluronan. Papworth J, Colville-Nash PR, Alam CAS, Seed MP, Willoughby DA (1996). Royal Society of Medicine Round Table Series 45:187-192.
26. Possible Mechanism for the mode of action of Hyanalgese-D.  Moore AR, Seed MP. Royal Society of Medicine Round Table Series 45:193-195.
27. Hyaluronan inhibits neutrophil-endothelial cell adhesion. Moore AR, Seed MP, Freemantle CN, Brown JR, Alam CAS, Willoughby DA (1996). Progress in Rheumatology VI: 64-68.
28. Restriction of new blood vessel growth points to a new approach to arthritis therapy. Seed MP. Hope 20:8 (1996).
29. The effects of systemic and topical angiostatic therapies on inflammatory angiogenesis. Moore AR, Alam CAS, Colville-Nash PR, Papworth J, Freemantle CN, Brown JR, Seed MP, Willoughby DA (1996). Progress in Rheumatology VI: 69-75.
30. Substance-P: a target for the actions of hyaluronic acid in combination with diclofenac?. Moore AR, Papworth JL, Alam CAS, Seed MP, Willoughby DA (1996). Progress in Rheumatology VI: 81-85.
31. Manipulating angiogenesis shows potential as RA therapy. Seed MP, Colville-Nash PR, Alam CAS, Willoughby DA (1996) Rheumatology News 24(1):2.
32. Additional Comments on non-steroidal anti-inflammatory drugs and topical analgesia (Letter). Willoughby DA, Moore AR, Papworth J, Seed MP (1996). Pain 64:205.
33. Arthritis 1996: Advances and Commercial Opportunities. Seed MP, Willoughby DA, Henderson B (1996). Book. Publ. Connect Pharma, (Oxford).
34. The effects of X-rays on experimental arthritis in the rat. Seed MP, Parker RJ, Trott K (1995). Stralentherapie und Onkologie 9: 534-538.
35. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Freemantle C, Alam CAS, Brown J, Seed MP, Willougby DA (1995) Int J Tiss React XVII: 157-166.
36. The inhibition of neutrophil-endothelial cell adhesion by hyaluronan, a ligand for ICAM-1. Seed MP, Freemantle, Brown J, Alam CAS, Willoughby DA (1995) Royal Society for Medicine Round Table Series 40:82-88.
37. The inhibition of tumour growth by topical hyaluronan and diclofenac sodium in combination (HYAL EX-0001). Freemantle C, Seed MP, Brown J, Alam CAS, Asculai S, Willoughby DA (1995) Royal Society for Medicine Round Table Series 40:89-97.
38. The delivery of diclofenac to pathological tissues by hyaluronan (HYAL EX-0001). Seed MP, Alam CAS, Brown J, Freemantle CN, Willoughby DA (1995). Royal Society for Medicine Round Table Series 40:74-81.
39. Inflammatory factors in osteoarthritis and rheumatoid arthritis. J Nurse (1995). Publishers Pfizer Inc NY, Seed MP scientific advisor (1994).
40. The Pharmacological modulation of angiogenesis in chronic granulomatous inflammation. Colville-Nash PR, Alam CAS, Appleton I, Brown JR, Seed MP, Willoughby DA (1995). J Pharmacol Exp Ther 274:1463-1472.
41. The use of topical hyaluronan improved targeting technology (HITT) for the modulation of angiogenesis by diclofenac (HYAL CT-2101) and cortisone (HYAL CT-1185). Alam CAS, Seed MP, Willoughby DA (1995) Royal Society of Medicine Round Table Ser 36:68-72.
42. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with Hyaluronan. Alam CAS, Seed MP, Willoughby DA (1995) J Pharm Pharmacol: 47:407-411.
43. Topical diclofenac and hyaluronan in combination results in angiostatic activity in the murine chronic granulomatous air pouch. Alam CAS, Seed MP, Willoughby DA (1994). Royal Society for Medicine Round Table Ser. 33:21-31.
44. Gender differences in inflammation-induced cartilage damage in rodents. The influence of sex steroids. da Silva JAP, Larbre J-P, Seed MP, Cutulo M, Villagio B, Scott DL, Willoughby DA (1993)J Rheumatol 21:330-337.
45. Editorial. Seed MP (1993) Eur J Rheum Inflamm 13: 1-2.
46. Rapid quantitation of joint destruction in irritant monoarticular arthritis induced by heat killed Mycobacterium tuberculosis. Seed MP, Hambleton PH, Bowden AR, Clements Jewery SCJ, Gardner CR (1993). Eur J Rheum Inflamm 13:27-33.
47. The current state of angiostatic therapy, with special reference to Rheumatoid Arthritis. Colville-Nash PR & Seed MP (1993). Current Opinions in Investigative Drugs 2:763-813.
48. Inflammation, prostaglandins, and loss of function. Willoughby DA, Colville-Nash PR, Seed MP (1993). J Lipid Mediators 6:287-293.
49. The inhibition of interleukin-1ß -induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor, U27391.  Seed M.P., Cheung C.Y., Thomson T.A., Gardner C.R., Atkins R.M., Elson C.J. (1993). Ann Rheum Dis 52:37-43.
50. The endothelial cell, a constitutive component of rheumatoid arthritis ripe for exploitation? Seed M.P., Willoughby D.A. (1992). Eur J Rheumatol Inflamm. 12:31-46.
51. Are we seeking the correct therapeutic targets? Willoughby D.A., Seed M.P. (1992) Int J Tiss React XIV: 77-90.
52. Mycobacterium tuberculosis-induced monoarticular arthritis, a new in vivo model for the assessment of antirheumatic drugs. Seed M.P., Parker F.L., Johns S., Curnock A.P., Bowden A., Gardner C.R. (1991). Clin Rheum 10:461-462.
53. Investigation of the role of metalloproteinases in recombinant interleukin-1ß -induced degradation of rat femoral head cartilage. Seed M.P., Thomson T.A., Gardner C.R. (1991) Drug Exp Clin Res. 17: 355-362.
54. New Areas for the Therapeutic Intervention in the Treatment of Autoimmune Disease. Willoughby D.A., Moore A.R., Seed M.P., Colville-Nash P. & Chander C. (1991). Therapie 46: 461-7.
55. Mechanisms of Cartilage Degradation. Seed M.P., Moore A.R., Desa F.M. & Willoughby D.A. (1991) Actualités en Physiopathologie et Pharmacologie Articulaires Publ Masson, Paris. 332-342.
56. Studies on Interleukin-1B - induced glycosamonoglycan loss from rat femoral head cartilage in vitro. Clay K., Seed M.P. & Clements-Jewery S.(1989). J Pharm Pharmacol 41: 503-504.
57. The effect of porcine catabolin on proteoglycan loss from various sources of cartilage. Rising T.J., Seed M.P. & Griffiths R.J. (1987) Arthritis & Rheumatism Council for Research. Conf. Proc. No. 2: 85-88.
58. Some observations on the pharmacology of `Deep Heat', a topical rubifacient. Collins A.J., Notarianni L.J., Ring E.F.J. & Seed M.P. (1983) Ann Rheum Dis 43: 411-415.
59. Influence of gestation on prostacyclin synthesis by the human pregnant myometrium. Seed M.P., Williams K.I. & Bamford D.S. (1983) In 'Prostacyclin in pregnancy', pp 31-36. Ed. P.J.Lewis, Raven Press N.Y.
60. Influence of stimulant and relaxant drugs on myometrial prostacyclin formation. Williams K.I., El-Tahir K.E.H. & Seed M.P. (1983) In 'Prostacyclin in pregnancy', pp 141-145. Ed. P.J.Lewis, Raven Press N.Y.

• Member of Council, British Pharmacological Society
• Fellow, Society of Biology
• Trustee, League of Mercy
• Honorary Senior Lecturer, Barts and the London School of Medicine and Dentistry
• Education & Outreach Committee, British Pharmacological Society
• Membership Secretary, British Inflammation Research Association
• Fellow Royal Society of Medicine
• Consulting Editor Inflammopharmacology
• RSPCA Rheumatoid Arthritis Research Models Working Group
• Member: British Society for Rheumatology

Meeting Abstracts

1. Development of a robust rat model of glucocorticoid induced osteoporosis as assessed by μCT, S.E.M. and confocal LM. Seed M, Zigmund T, Kvasnica L, Burnet M, Boyde A, Ray D. Sept 2012. 17th International Conference of the Inflammation Research Association, USA.
2. Targeting therapeutics to arthritic joints by antibody specific to post-translationally modified collagen type-II. Hughes, C, Faurholm B, Dell’Accio F, Manzo A, Seed M, Eltawil NM, Amarelli A, Al-Kashi A, Winyard P, Chernajovsky Y. Ann Rheumm Dis 2012 71:A7. EWRR Stockholm.
3. Pre-conditioned MAPK activated protein kinase-2 (MK-2) responses of macrophages to p38 inhibition in the absence of intracellular inhibitor, SB203580. Yousaf  N, Malik N, Lees M, Moradi V, Laufer, S, Albrecht W, Schett G, Burnet M, & Seed M. Sept 2012. 17th International Conference of the Inflammation Research Association, USA.
4. 3D imaging methods in quantifying rat femoral bone changes with prednisolone administration:  µCT, SEM and confocal LM. T. Zikmund, L.Kvasnica, D.W. Ray,  M.P. Seed,  M. Burnet, A. Boyde. the International Workshop on Musculoskeletal and Neuronal Interactions, University of Ipswich.
5. Targeting Therapeutics To Arthritic Joints. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, et al. Annual Meeting of the British-Society-for-Rheumatology 2011 Rheumatology 50: 127-127. 2011.
6. Transient Exposure By Macrophages To A P38 Map Kinase Inhibitor Induces Rebound Inhibition Of Mapk-Activated Protein Kinase-2 Signalling. Malik N, Lees M, Moradi V, Albrecht W, Laufer S, Schett G, Burnet M, Seed M. Annual Meeting of the British-Society-for-Rheumatology 2011. Rheumatology 50: 51-51. Apr 2011.
7. In Silico Enzyme And Receptor Fit Screening Of Antirheumatic Diglucopyranosylamines: A Novel Application For Determining Mechanism Of Action Of Novel Anti-Rheumatic Drug Candidates. Seed MP, Langer T 10th World Congress on Inflammation, Paris, Inflammation Research 2011 60: 288-289.
8. Mc3 Agonists As Novel Pro-Resolving Therapeutics. Montero-Melendez T, Jonassen T, Seed M, Perretti M. 10th World Congress on Inflammation, Paris, Inflammation Research 60: 269-269. Jun 2011.
9. Differential Joint Disease Expression In Pristane-Induced Arthritis-A Systematic Profile Of Disease Progression In Da/Olahsd Rats. Malik N, Burnet M, Jones R, Schett G, Seed M. 10th World Congress on Inflammation, Paris, FRANCE, 25 Jun 2011 - 29 Jun 2011. Inflammation Research 60: 186-186. Jun 2011.
10. Molecular Engineering Of Short Half Life Small Peptides (Vip, Alpha MSH And Gamma 3msh) Into Latent Associated Peptide (Lap) Results In Targeted Anti-Inflammatory And Anti-Rheumatic Therapeutics. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed MP, Perretti M, Chernajovsky Y. 10th World Congress on Inflammation, Paris, Inflammation Research. 60: 43-43. Jun 2011.
11. AP214, a new MSH analogue, possesses anti-inflammatory activities. Montero T, Jonassen T, Seed M, Perretti M. British Pharmacological Society Christmas Meeting 2009.
12. The poly-anionic sugar sucrose octa-sulphate is an oral Anti-rheumatic and anti-erosive metabolite of sucralfate Jones R., Mancini J., Lees M., Roitt I., Burnet M., Seed M. Inflammation Research (2008) 57(s2): s105-6
13. Preconditioning lymphocytes with p38 MAPk inhibitors, and not accessory cells, prevents con-a-induced lymphocyte responses. V Moradi, E Johnson, L Dugo, V Holan, M Burnet, S Laufer, MSeed* Inflammation Research (2008) 57(S2) S104.
14. Intracellular signalling pathways controlling inflammation: potential for pharmacological control of chronic inflammatory disease.  (Oral Plenary) M. P. Seed  Inflammopharmacology 2009, 16:307.
15. Anti-rheumatic activity and cytokine synthesis inhibition by the oliosulphated disaccharide sucrose octasulphate. M. Lees, L. Dugo, Z. Ganiyu-dada, J. Mancini, M. Burnet, M. Seed. Inflammopharmacology 2009, 16:319-320.
16. p38 MAP kinase triggers dendritic or accessory cells in the allogeneic mixed lymphocyte and Con-A – induced lymphocyte responses. V. Moradi, E. Johnson, L. Dugo, V. Holan, M. Burnet, S. Laufer, M. Seed.  Inflammopharmacology 2009, 16:323-324.
17. A simple score for assessing bone erosion in rodent arthritic paws visualised by micro focal computer tomography Xray. J. Mancini, M. R. Jones, C. Alam, M Burnet, M. P. Seed. Inflammopharmacology 2009, 16:324.
18. Dendritic Cell:T Cell interactions and p38 MAPKinase Inhibition. Seed M, Johnson E, Burnet M, Holan V, Laufer S. 8th World Congress on Inflammation, Oral. Inflammation Research (2007) 56(S3):S433-434.
19. Inhibitory-KappaB kinase (IKK) alpha is required for antigen driven inflammation. Johnson E, Seed M, Lawrence T. 8th World Congress on Inflammation, Oral. Inflammation Research (2007) 56(S3):S375.
20. Antirheumatic/TNF action by free & polysulphated diglucopyranosylamine. Jones MR, Mancini M, Lees M, Gutke H-J, Burnet M, Roitt I, Seed MP. 8th World Congress on inflammation (Oral). Inflammation Research (2007) 56(S3): S433.
21. p38 MAPKinase inhibitor prodrugs tropic for macrophages and neutrophils exert enhanced anti-inflammatory activity in IBD and collagen induced arthritis models.  Guse J-H, Burnet M, Luik S, Seed M, Laufer S, Seed M, Holan V, Fiorucci S (2007) 8th World Congress on inflammation (Poster). Inflammation Research 56(S3):S434.
22. Inhibitory-κB kinase (IKK)-α is required for cell mediated immunity. Johnson EVE, Seed MP & Lawrence T (2007). Immunology, 120 (S1), 74.
23. The stimulation of HO-1, a common mechanism for cytokine suppression by Diacerein in murine and human macrophages. Colville-Nash PR, Ficheux H, Johnson E, Ayoub S, Mistry D, Mehet D, Pastel S, Newson J, Domogala F, Seed M (2006). Inflammation Research 55(S2):S118.
24. Inhibitory-κB kinase (IKK)α is required for antigen-driven inflammation. Johnson E, Lawrence T, Seed MP (2006). Inflammation Research 55(S2):S126. Gordon Van Armand Scholarship & Prize.
25. Inhibition of p38 kinase prevents T-cell responsiveness to allogenic dendritic cells. Johnson E, Laufer S, Holan V, Burnet M, Seed M (2006). Inflammation Research 55(S2):S118.
26. The role of IkBkinase (IKK)α in dendritic cell function and adaptive immunity. Sutton, E Johnson, M Seed, T Lawrence (2005). Immunology 116 (S1), 13.
27. The induction of apoptosis may contribute to the immuno-modulatory actions of 15d-PGJ2 in T lymphocyte driven inflammation in vivo. Trivedi SG, Colville-Nash PR, Seed MP (2005) Inflammation Research 2005 54 S125. Gordon Van Armand Scholarship & Prize.
28. Inhibition of antigen-induced arthritis by diglucosylamine, an immunomodulator identifed from spleen. Bolton C, Trivedi SG, Johnson E, Wood EG, Seed MP (2005). Inflammation Research 54 S121.
29. Cyclo-oxygenase-3 immunoreactivity in naïve and inflammatory leucocytes, and the modulation of COX activity in vivo by acetaminophen. Ayoub SS, Read EJ, Sawatzky D, Willougby DA, Seed MP (2004). Inflammation Research 2004 53 (Suppl 3): S229.
30. A novel role for 15 deoxy  12-14 PGJ2 in vivo: immunomodulatory activity in antigen induced arthritis. Seema Gor Trivedi, Seed MP, Colville-Nash PR Inflammation Research 2004 53 (Suppl 3) S233.
31. COX inhibitor prodrugs: tropism for macrophages / neutrophils enhances anti-inflammatory activity.  Wolff M, Gutke HG, Meindl T, Guse J, Margutti S, Flohr C, Seed M, Laufer S, Albrecht W, Burnet M. Inflammation Research 2004 53 (Suppl 3): S209.
32. Effects of Diacerein on heme-oxygenase-1 and nuclear factor Kappa B. P Colville-Nash, D Mistry, M Seed, D Mehet, F Domagala, H Ficheux D Provvedini, D Willoughby (2003). Osteoarthritis Cartilage 11(SA): S70.
33. Heat Shock proteins: Role in chondrocyte protection against blood for autologous transplantation. Sawatzky D, Foster R, Seed M, Willoughby DA (2003). Inflammation Research 52 (S2):S133.
34. Double blind multicentre comparison of glucosamine and chondroitin with carprofen in clinical canine osteoarthritis. Seed M, McCarthy G, Barabas S, Jones S (2003). Inflammation Research 52(S2):S120.
35. Clinical Trial comparing glucosamine with chondroitin sulphate to carprofen for the treatment of osteoarthritis in dogs – Preliminary findings. McCarty G, Seed M, Barabas S, Jones B. J Vet Intern Med. (2003) 17(3):426.
36. Heat-shock proteins and their role in chondrocyte protection, an application for autologous transplantation.  MP Seed, DA Sawatzky, R Foster and DA Willoughby (2003). Inflammopharmacology 11(S) 2003.45-46.
37. Depletion of substance P in the mouse by diclofenac. Papworth J, Colville-Nash PR, Alam CAS, Seed MP, Willoughby DA (1997) Eur. J.Pharmacol. 325:R1-R2.
38. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan (HYAL CT-1101). Alam CAS, Seed MP, Willoughby DA (1995). Proceedings of the Western Pharmacological Society.
39. Inhibition of colon-26 tumour growth and angiogenesis: Findings on p.o. & topical NSAIDs in hyaluronan in vivo, & using Cox-1 and Cox-2 inhibitors in vitro. Seed MP, Freemantle C, Alam CAS, Colville-Nash PR, Gilroy D, Brown J, Papworth J, Somerville K, Willoughby DA (1996). Prostaglandins Leukotrienes and Essential Fatty Acids 55(S1):180.
40. Chondrodestructive and chondroneutral actions of cyclo-oxygenase-1 and -2 inhibitors. Gilroy D, Greenslade K, Tomlinson A, Seed MP, Willoughby DA (1996). Prostaglandins Leukotrienes and Essential Fatty Acids 55(S1):P91.
41. The co-administration of hyaluronan with cyclosporin greatly increases cyclosporin efficacy in rat models of cell-mediated immunity. Seed MP, Moore AR, Gowland G, Willis D, Willoughby DA (1996) Rheumatol. Eur. 25(S1):86.
42. Neutrophil elastase and metalloproteinase activity and cartilage loss in granulomatous inflammation. Seed MP, Trancart MM, Moore AR, Azam Z, Prigent D, Willoughby DA (1996) Rheumatol. Eur. 25(S1):86.
43. Proteoglycan degrading activity within granulomatous inflammatory tissue. Prigent D, Trancart MM, Seed MP (1996).
44. The inhibition of neutrophil adhesion in vitro and in vivo by hyaluronan, a ligand for ICAM-1. Seed MP, Freemantle C, Gustafson S, Brown J, Alam CAS, Perretti M, Colville-Nash PR, Newbold P, Dwivedi A, Carrier M, Willoughby DA.Rheumatol. Eur. 25(S1):88.
45. Angiostasis and vascular regression in chronic granulomatous tissue induced by diclofenac with HYAL HIT technology. Alam CAS, Seed MP, Brown J, Asculai SS, Willoughby DA (1995). Inflammation Research 44:S229.
46. The degradation of cartilage by bone derived factors. Seed MP, Willoughby DA (1995). Inflammation Research 44:S254.
47. Metalloproteinase (MMP) regulation and cartilage matrix loss during granulomatous inflammation in elastase deficient Chediak Higashi mice. Seed MP, Trancart MM, Moore AR, Azan Z, Prigent D, Willoughby DA (1995). Inflammation Research 44:S255.
48. The inhibition of neutrophil-endothelial cell adhesion by hyaluronan, a ligand for ICAM-1. Seed MP, Freemantle C, Gustafson S, Brown J, Alam CAS, Perretti M, Newbold P, Dwivedi A, Carrier M, Willoughby DA (1995).  Inflammation Research 44:S2.
49. Proteoglycan degrading activity in granulomatous inflammation. Prigent D, Trancart MM, Seed MP (1995). Inflammation Research 44:S257.
50. Chondroneutral and chondrotoxic diversity of non-steroidal anti-inflammatory drugs in Mycobacterium tuberculosis monoarticular arthritis.  Seed MP, Bowden AR, Parker FP, Johns S, Curnock A, Gardner CR (1995). Br J Rheum 34(S2):15.
51. Angiostatic steroid and angiogenic heparin therapy results in altered granuloma development and cartilage destruction. Colville-Nash PR, Seed MP, Willoughby DA.(1995) Annals Rheum Dis 54:777.
52. Regression of granulomatous tissue neovasculature with angiostatic steroid therapy. Seed MP, Alam CAS, Willoughby DA (1995). Annals Rheum Dis 54: 777.
53. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan (HYAL CT-1101). Alam CAS, Seed MP, Willoughby DA (1995) Annals Rheum Dis 54: 757.
54. The modulation of inflammatory mono-arthritis (IMA) by low doses of radiation. Seed MP, Parker RJ, Trott K (1995) Rheumatol Eur 24(S3):187.
55. The degradation of cartilage by soluble bone-derived factors. Seed MP, Willoughby DA (1995). Rheumatol Eur 24(S3):315.
56. Chondro-neutral and -destructive NSAIDs in inflammatory mono-articular arthritis. Seed MP, Bowden AR, Gardner CR (1995). Rheumatol Eur 24(S3):323.
57. Étude des effets de l'interleukine-1 sur le cartilage en fonction du sexe et de l'age. Larbre JP, da Silva JAP, Moore AR, Spector TD, Seed MP, Willoughby DA (1993). Revue de Rheumatisme 60:E07.
58. Étude des effets de l'interleukin 1 in vitro sur le cartilage humain en culture. Larbre JP, Da Silva P, Hill R, Moore AR, Seed MP, Willoughby DA. (1992). Revue de Rheumatisme 59: 688.
59. Angiogenesis during the development of chronic granulomatous tissue as assessed by vascular casting in vivo. P.R. Colville-Nash, M.P. Seed, D.A. Willoughby. Br J Pharmacol (1992) 107: 259P.
60. Antirheumatic drugs and the development of vasculature in murine chronic granulomatous air pouches. P.R. Colville-Nash, M.P. Seed, D.A. Willoughby. Br J Pharmacol (1992) 107: 421P.
61. Effect of the metalloproteinase inhibitor, U27391, on the degradation of rat or human  femoral head cartilage by interleukin-1ß. Seed M.P., Ismael S., Thomson T.A., Gardner C.R., Elson C.J. (1992). In: Articular cartilage and Osteoarthritis. Eds Kuettner K.E., Schlayerbach R, Peyron J.G., Hascall V.C. Publ Raven Press NY. p695.
62. Sodium Aurothiomalate Inhibits interleukin-1ß -induced degradation of rat femoral articular cartilage in vitro. Seed M.P. & Cheung C.Y.C. (1990).
63. Evidence that lowered whole blood platelet-activating factor accompanies gestation on normotensive and hypertensive rats. Neill J.C. & Seed M.P. (1986) Br J Pharmacol 88: 433P.
64. Effects of oxytocic drugs on prostaglandin synthesis by human pregnant myometrium. Hensby C.N., Seed M.P. & Williams K.I. (1985) Br J Pharmacol 86: 806P.
65. Estimation of small quantities of prostacyclin using rabbit platelet rich plasma pre-treated with papaverine. Bamford D.S., Seed M.P. & Williams K.I. (1982) Br J Pharmacol 77: 164P.
66. Influence of stimulant and relaxant drugs on prostacyclin production by rat pregnant myometrium. El-Tahir K.E.H., Seed M.P. & Williams K.I. (1982) Br J Pharmacol 74: 794P.

Conference Proceedings:

1. Anti-rheumatic activity and cytokine synthesis inhibition by the oligosulphated disaccharide sucrose octasulphate. M Lees, L Dugo, Z Ganiyu-dada, J Mancini, M Burnet, M Seed. 8th Jenner Glycobiology and Medicine Sympsoium, October 2007.
2. Inhibitory-B kinase (IKK) is required for antigen-driven inflammation in vivo: E.V.E. Johnson, K Sutton, MP Seed & T Lawrence.  16th European Congress of Immunology, Paris, September 2006, PC2670.
3. Cell-mediated immunity is dependent on Inhibitory-B kinase (IKK) activity: E.V.E. Johnson, K Sutton, MP Seed & T Lawrence.  Cell Signalling 2006, 3rd Annual Symposium, Dundee, June 2006.
4. Inhibitory-B kinase (IKK): a novel target for the treatment of autoimmune disease: E.V.E. Johnson, K Sutton, MP Seed & T Lawrence.  Bioscience 2006, House of Commons, May 2006.   
5. Inhibitory-B kinase (IKK) is required for cell-mediated immunity: E.V.E. Johnson, K Sutton, MP Seed & T Lawrence.  British Pharmacological Society, Focused Meeting: Controlling Acute Inflammation, London, April 2006.  
6. Choices in arthritis pain relief, which cyclo-oxygenase: Cox-1, 2, or 3? Seed MP. Pain Treatment Panorama. Lithuanian Pain Society 6th Annual General Meeting, Druninskai. Plenary. April 2006. p17-19.
7. Inhibitory-κB kinase (IKK)-α is required for antigen-driven inflammation. Johnson EVE, Seed MP and Lawrence. British Pharmacological Society Special Interest Group Meeting, Controlling Acute Inflammation. London, April 2006.
8. A novel role for 15 deoxy  12-14 PGJ2 in vivo: immunomodulatory activity in antigen induced arthritis. Seema Gor Trivedi, Seed MP, Colville-Nash PR Inflammation Research Association, New York. Gordon van Armand (Scholarship Prize).
9. Cyclooxygenase-3 (COX-3) immunoreactivity in circulating and inflammatory pleural washout leucocytes, and the functional modulation of pleurisy by paracetamol. Jones, E, Ayoub S, Willoughby DA, Seed MP (2005). 2nd James Black Conference, New Targets in Pain and Inflammation, Oxford. October 2004, poster.
10. Heme-oxygeanse-1 (HSP-32), a novel target for the induction of resolution in inflammation. MP Seed (2003). Anti-inflammatory Therapeutics, SMI Conferences.
11. Chondroprotection in sport Seed MP. British Association of Sport & Exercise Medicine, Cumbria, 2002.
12. Angiogenesis in chronic inflammation. Seed MP. BIRAs Symposium: Inducible enzymes and matrix metalloproteinses in Inflammation, London 1999.
13. The Pharmacology of angiogenesis in inflammation. Seed MP. Imperial College Symposium on drug targets in Asthma, London  1998.
14. Inhibition of colon-26 tumour growth and angiogenesis: findings on p.o. & topical NSAIDs in hyaluronan in vivo, &  using Cox-1 and Cox-2 inhibitors in vitro. Seed MP, Freemantle C, Alam CAS, Colville-Nash PR, Gilroy D, Brown J, Papworth J, Somerville K, Willoughby DA (1997). 10th International Conference on Prostaglandins and Related Compounds, Vienna.
15. Neutrophil adhesion inhibition by hyaluronan. Seed MP, Freemantle C, Gustafson S1, Brown J, Alam CAS, Peretti M, Colville-Nash PR, Newbold P, Dwivedi A, Carrier M, Willoughby DA (1996). William Harvey Res. Conference Cyclo-oxygenase-2 and adhesion molecules. New Orleans.
16. Diclofenac with HYAL HIT Technology (HYAL (CT-1101) induces angiostasis and vascular regression in chronic granulomatous inflammation. Alam CAS, Seed MP, Willoughby DA (1995) 6h Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva. March 1995, abstract 163.
17. Oral and topical NSAIDs in combination with Hyaluronan inhibit angiogenesis in chronic granulomatous inflammation. Alam CAS, Colville-Nash PR, Seed MP, Willoughby DA (1994). Proc. 9th Int. Conf. Prostaglandins and Related Compounds, Florence. p38.
18. NSAID-induced acceleration of cartilage degradation in monoarticular arthritis. Seed MP, Kawabata K, Willoughby DA. (1994) Proc. 9th Int. Conf. Prostaglandins and Related Compounds, Florence. p37.
19. Analgesia and angiostasis induced by hyaluronan and diclofenac during inflammation in vivo. A common pathway? Alam CAS, Seed MP, Willoughby DA (1994). XII Int. Conf. Pharmacology, Montreal P10.5.7 (382).
20. Inflammation, prostaglandins, and loss of function. Willoughby DA, Colville-Nash PR, Seed MP (1992). 8th International Conference on Prostaglandins and Related Compounds, Montreal, Canada.
21. Analgesia and angiostasis in the treatment of rheumatoid arthritis: a linking hypothesis involving the effects of topical hyaluronate and NSAID combination therapy.  Alam CAS, Seed MP, Willoughby DA (1994). Proc. 4th Biannual Congress Int. Soc. Rheum. Therapy, Washington.
22. Regression of the neovasculature in murine chronic granulomatous inflammation. Alam  CAS, Seed MP, Asculai SS, Willoughby DA (1994). Proc. of the Inflammation Research Association, Philadelphia, P14.
23. Angiogenesis in inflammation: Serine protease inhibition in vivo is angiostatic. Seed MP, Colville-Nash PR, Alam C, Willoughby DA.  Inflammation '93, Vienna (1993).
24. Effect of angiostatic therapy in an in vivo model of pannus mediated cartilage degradation. Colville-Nash PR, Seed MP Willoughby DA.  4th. Inter-Science World Conference on Inflammation, Geneva 1991.
25. Investigation of the role of metalloproteinases in recombinant human interleukin-1ß -induced degradation of cartilage from rat and human.  Seed MP, Ismaiel S, Thomson TAT, Gardner CR, Elson CJ. 4th. Inter-Science World Conference on Inflammation, Geneva 1991.
26. Investigation of the role of metalloproteinases in recombinant human interleukin-1ß -induced degradation of cartilage from rat and human. Seed MP, Clay K, Gardner CR.  4th. Inter-science World Conference on Inflammation, Geneva 1991.
27. A comparison of Mycobacterium tuberculosis and zymosan -induced arthritides with respect to steroidal and non-steroidal anti-inflammatory therapy. Seed MP, Parker FL, Johns S, Curnock AP, Bowden A, Gardner CR.  4th. International Congress on Inflammation, Rome 1991.
28. Evidence that pregnancy-induced hypotension in the spontaneously hypotensive rat is not caused by the release of platelet activating factor.  Neill JC, Seed MP.  6th Conference on Prostaglandins and Related Compounds (1986).
29. Estimation of small quantities of prostacyclin using rabbit platelet rich plasma treated with papaverine. Seed MP, Bamford DS, Williams KI.  5th International Conference on Prostaglandins (1982)

British Pharmacological Society Council

British Pharmacological Society Committees

Inflammopharmacology

Inflammation Research Association

Gordon Van Armand Awards

British Inflammation Research Association

International Association of Inflammation Societies

League of Mercy

Royal Society of Medicine

Society of Biology

British Society for Rheumatology

European Workshop of Rheumatology